Vivus's erectile dysfunction drug meets endpoints in second pivotal trial
This article was originally published in Scrip
Executive Summary
Vivus's PDE5 inhibitor avanafil has met its co-primary endpoints in diabetic men with erectile dysfunction (ED), show data presented last week at the American Urological Association (AUA) in San Francisco. The results mark the second successful pivotal trial for avanafil; last year it was positive in men with general ED, prompting the company to say that it would file the drug late in 2010 or early in 2011 (scripnews.com, 23 November 2009).